GD
CytoMed Therapeutics Limited
GDTC · NASDAQ
$0.86 +6.87% (+$0.06)
1M -5.70%
Market Cap $13.0M
P/E Ratio -
Div. Yield -
ROE 70.74%
Piotroski F-Score Weak
2/9Valuation
44 /100
Fair P/S 20.28x
P/B 1.99x
P/E N/A
Growth
22 /100
Declining Rev. growth 4.42%
Book val. growth 123.05%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 20.48%
Net margin 754.67%
FCF margin 986.02%
Quality
1 /100
Poor ROIC 58.88%
ROE 70.74%
Asset turnover 0.08x
Debt
69 /100
Low Debt/Equity 0.07x
Current ratio 5.17x
Int. coverage -276.39x
Stability
13 /100
Unstable Beta 0.05x
Rev. volatility 229.77%
Profitable years 0
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na GDTC
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Chee Kong Choo
Employees
42
Headquarters
Singapore
Nadcházející události
13 LIS
Earnings
Upcoming earnings report